Evidence map›Paper›PMID 42351219›Full record

ArticleVirology journal2026

HPV epidemiologic study in Bengbu, China, involving 123,808 women, 2014-2023.

Xiaowen Hu, Manman Zhu, Liqun Wang, Kang Yang, Tao Xu, Yu He

Abstract read
In one paragraph

Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaowen HuDepartment of Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Manman ZhuBengbu Medical University, Bengbu, Anhui Province, China.
Liqun WangDepartment of Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Kang YangDepartment of Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China.
Tao XuSchool of Laboratory Medicine, Bengbu Medical University, Bengbu, Anhui, China. taoxu@bbmc.edu.cn.
Yu HeDepartment of Gynecology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China. byyfyhu@126.com.

Funding

Bengbu Medical University 2023byzd057Office of Science and Technology of Anhui Province 202427b10020073
6 · The paper itself

Abstract

backgroundCervical cancer is largely caused by persistent high-risk human papillomavirus infection, and due to the wide regional variations in HPV type distribution, the long-term epidemiological characterization of HPV infection in China has not yet been sufficiently studied. Cervical cancer screening and the creation of HPV vaccination programs in a given area are significantly influenced by the epidemiological features of HPV infection in that area. In order to provide an epidemiological foundation for the development of an early screening and prevention strategy for cervical cancer, we examined the epidemiological features of HPV infection in a community in the northern part of Anhui Province, China, in this research.

methodsThis study examined 123,808 cervical exfoliated cell samples that were taken from female patients at Bengbu Medical University's First Affiliated Hospital between January 2013 and December 2023. An HPV genotyping kit was used for HPV-DNA testing. Age, year, and numerous patterns of HPV infection were taken into consideration when analyzing the prevalence of HPV infection. Differences in prevalence between years and age categories were compared using the χ2 test. Multivariable logistic regression models were used to assess the associations of age, calendar year, and their interaction with the risk of infection by different HPV types, with adjustment for potential confounding factors.

resultsThe detection rate of high-risk types (HR-HPV) was 14.24% (17,630/123,808), while the overall prevalence of HPV infection for the 28 HPV genotypes was 17.62% (21,674/123,808). The age-specificity of HPV infection displayed a bimodal distribution with two distinct peaks: 17.39% of people under 25 had an infection, while 21.14% of people between the ages of 60 and 64 had an infection. According to annual distribution statistics, the overall prevalence of HPV infection was low in 2014 and 2015, rapidly increased to 24.19% (2573/10637) in 2016, peaked at 27.04% (2238/8278) in 2017, then decreased annually to a low of 13.44% (2178/16207) in 2019, and remained relatively stable until 2023, when it increased once more to 17.62% (2545/11443). The top five HR-HPV prevalence rates, according to the study of genotype-specific statistics, were HPV-16 (4.01%, 4968/123808), -52 (2.95%, 3651/123808), -58 (2.12%, 2629/123808), -56 (1.05%, 1298/123808), and 51(0.98%,1216/123808). The most prevalent form of infection among the positive cases was HPV, with a single infection rate of 72.85% (12844/17630). Age was positively associated with infection risk for HPV16, HPV31, HPV33, HPV35, HPV52, HPV56, HPV58, and HPV68 (OR = 1.12-1.26). Infection risks for the majority of HPV types declined significantly over time (OR = 0.57-0.82). Significant age-by-year interaction effects were observed for 10 types, indicating heterogeneity in temporal trends across age groups.

conclusionThis study offers the most comprehensive information on the epidemiological features of HPV infection in Bengbu and even in northern Anhui Province. It also serves as a foundation for the development of cervical cancer prevention and control measures in this area.

Indexed as

Human Papillomavirus VirusesPapillomaviridaePapillomavirus InfectionsAdolescentAdultAgedCervix UteriChinaDNA, ViralEpidemiologic StudiesFemaleGenotypeHumansMiddle AgedPrevalenceUterine Cervical NeoplasmsDNA, ViralEpidemiologyGenotypeHuman papillomavirus(HPV)

Identifiers

PMID42351219
PMCPMC13621593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.